Alvimopan (Alvimopan) Patent Expiration, LOE Window & CMS Spending
Alvimopan (Alvimopan) by Endo Pharmaceuticals: Multi-Source Generic Molecule, 3 AB generics, $47K 2024 CMS Part D & Medicaid spend, and $4,975 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Endo Pharmaceuticals |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $47K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $47K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($4,975 intro WAC) |